BioCentury | Jun 22, 2020
Deals

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

Codiak is extending its exosome platform to AAVs by partnering with Sarepta to overcome two major obstacles for nucleic acid therapies: tissue-targeting and repeat dosing. The resulting products would be vectors within vectors, with multiple...
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19. Meanwhile, a repurposing screen by Aldeyra could yield...
BC Extra | Dec 16, 2019
Clinical News

Novartis’ asthma failure weighs on Gossamer’s shares ahead of readout

The latest failure of asthma therapy fevipiprant from Novartis in two Phase III studies dimmed hopes for Gossamer’s lead program, which aims for the same target. Novartis AG (NYSE:NVS; SIX:NOVN) said Monday that pooled results...
BC Extra | Oct 22, 2019
Clinical News

Novartis still bullish on asthma program despite pair of Phase III misses

Novartis is looking ahead to a second set of late-stage readouts next quarter for fevipiprant to treat asthma, despite the candidate’s failure to meet the primary endpoint in two Phase III studies. Along with its...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Extra | Mar 13, 2019
Company News

FDA approves Aerie glaucoma therapy Rocklatan

Aerie said late Tuesday FDA approved Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is a fixed-dose combination of Aerie's Rhopressa netarsudil 0.02%, a dual inhibitor of...
BC Week In Review | Feb 21, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
BC Extra | Feb 19, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
BC Week In Review | Feb 15, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
Items per page:
1 - 10 of 672